Figure 4
Number of activated NK cells (CD69+) relative to total number of NK cells (CD16+ or CD56+; CD3−). Change from baseline (=100%) for all patients receiving doses ≥0.15 mg/kg AFM13 (n = 22).
Number of activated NK cells (CD69+) relative to total number of NK cells (CD16+ or CD56+; CD3−). Change from baseline (=100%) for all patients receiving doses ≥0.15 mg/kg AFM13 (n = 22).
